tbuckley/cabot-search huggingface dataset:
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
Authors: Jean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, Dmitriy Zamarin, Tara Mitchell, Gaetan Catala, Lauriane Eberst, Wolfgang Jacob, Anna-Maria Jegg, Michael A Cannarile, Carl Watson, Galina Babitzki, Konstanty Korski, Irina Klaman, Priscila Teixeira, Sabine Hoves, Carola Ries, Georgina Meneses-Lorente, Francesca Michielin, Randolph Christen, Dominik Rüttinger, Martin Weisser, Jean-Pierre Delord, Philippe Cassier
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background This phase Ib study evaluated the safety, clinical activity, pharmacokinetics, and pharmacodynamics (PD) of emactuzumab (anti-colony stimulating factor 1 receptor monoclonal antibody (mAb)) in combination with selicrelumab (agonistic cluster of differentiation 40 mAb) in patients with advanced solid tumors. Methods Both emactuzumab and selicrelumab were administered intravenously every 3 weeks and doses were concomitantly escalated (emactuzumab: 500 to 1000 mg flat; selicrelumab: 2 to 16 mg flat). Dose escalation was conducted using the product of independent beta probabilities dose-escalation design. PD analyzes were performed on peripheral blood samples and tumor/skin biopsies at baseline and on treatment. Clinical activity was evaluated using investigator-based and Response Evaluation Criteria In Solid Tumors V.1.1-based tumor assessments. Results Three dose-limiting toxicities (all infusion-related reactions (IRRs)) were observed at 8, 12 and 16 mg of selicrelumab together with 1000 mg of emactuzumab. The maximum tolerated dose was not reached at the predefined top doses of emactuzumab (1000 mg) and selicrelumab (16 mg). The most common adverse events were IRRs (75.7%), fatigue (54.1%), facial edema (37.8%), and increase in aspartate aminotransferase and creatinine phosphokinase (35.1% both). PD analyzes demonstrated an increase of Ki67 + -activated CD8 + T cells accompanied by a decrease of B cells and the reduction of CD14 Dim CD16 bright monocytes in peripheral blood. The best objective clinical response was stable disease in 40.5% of patients. Conclusion Emactuzumab in combination with selicrelumab demonstrated a manageable safety profile and evidence of PD activity but did not translate into objective clinical responses. Trialregistration number NCT02760797 .
Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19
Authors: Gregory Piazza, Umberto Campia, Shelley Hurwitz, Julia E. Snyder, Samantha M. Rizzo, Mariana B. Pfeferman, Ruth B. Morrison, Orly Leiva, John Fanikos, Victor Nauffal, Zaid Almarzooq, Samuel Z. Goldhaber
Journal: Journal of the American College of Cardiology (2020)

Cardiovascular complications, including myocardial infarction, ischemic stroke, and pulmonary embolism, represent an important source of adverse outcomes in coronavirus disease-2019 (COVID-19).To assess the frequency of arterial and venous thromboembolic disease, risk factors, prevention and management patterns, and outcomes in patients with COVID-19, the authors designed a multicenter, observational cohort study.We analyzed a retrospective cohort of 1,114 patients with COVID-19 diagnosed through our Mass General Brigham integrated health network. The total cohort was analyzed by site of care: intensive care (n = 170); hospitalized nonintensive care (n = 229); and outpatient (n = 715). The primary study outcome was a composite of adjudicated major arterial or venous thromboembolism.Patients with COVID-19 were 22.3% Hispanic/Latinx and 44.2% non-White. Cardiovascular risk factors of hypertension (35.8%), hyperlipidemia (28.6%), and diabetes (18.0%) were common. Prophylactic anticoagulation was prescribed in 89.4% of patients with COVID-19 in the intensive care cohort and 84.7% of those in the hospitalized nonintensive care setting. Frequencies of major arterial or venous thromboembolism, major cardiovascular adverse events, and symptomatic venous thromboembolism were highest in the intensive care cohort (35.3%, 45.9%, and 27.0 %, respectively) followed by the hospitalized nonintensive care cohort (2.6%, 6.1%, and 2.2%, respectively) and the outpatient cohort (0% for all).Major arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous thromboembolism occurred with high frequency in patients with COVID-19, especially in the intensive care setting, despite a high utilization rate of thromboprophylaxis.
OP0113 Increases in bone mineral density explain the reduction in incidence of nonvertebral fractures seen with antiresorptive therapy in women with postmenopausal osteoporosis
Authors: RD Wasnich, MC Hochberg, S Greenspan, PD Ross, PD Miller
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> A recently published meta-analysis of randomised, placebo-controlled trials of antiresorptive agents in postmenopausal women found a significant relationship between increases in bone mineral density (BMD) and reductions in risk of radiographic vertebral fractures, as well as a small risk reduction not explained by change in BMD.<sup>1</sup> It is unknown, however, whether a similar relationship exists between increases in BMD and a reduction in risk of clinical nonvertebral fractures. <h3>Objectives</h3> To examine the extent to which increases in BMD during antiresorptive therapy are associated with reductions in risk of nonvertebral fractures. <h3>Methods</h3> We performed a meta-analysis of all randomised, placebo-controlled trials of antiresorptive agents conducted in postmenopausal women with osteoporosis with available relevant data. A total of 15 such trials with usable data were identified including a total of 1911 women with incident nonvertebral fractures over 54,952 women-years of follow up. Poisson regression was used to estimate the association between increase in BMD (change in the treatment group – change in placebo group) and relative risk (RR) of nonvertebral fractures across all trials; separate models were constructed for change in spine BMD and change in hip BMD. <h3>Results</h3> Both models found a significant relationship between increases in BMD and reductions in nonvertebral fracture risk. For each 1 percent increase in bone mineral density at the lumbar spine, there was a 4.3 percent decrease in risk of nonvertebral fracture (P = 0.029); for each 1 percent increase in bone mineral density at the hip, there was a 8.8 percent decrease in risk of nonvertebral fracture (P = 0.016). In neither model was there a significant decrease in risk of nonvertebral fractures in the absence of increase in bone mineral density. Thus, an agent that increases spine BMD by 8% reduces nonvertebral fracture risk by about 40%, and an agent that increases hip BMD by 5% also reduces nonvertebral fracture risk by about 40%. <h3>Conclusion</h3> These data demonstrate that larger increases in BMD at both the spine and hip are associated with greater reductions in risk of nonvertebral fractures. Antiresorptive agents which do not produce large increases in BMD do not appear to and would not be expected to decrease the risk of nonvertebral fractures. <h3>Reference</h3> J Clin Endocrinol Metab. 2000;85:231–6
Correction: Variation in racial/ethnic disparities in COVID-19 mortality by age in the United States: A cross-sectional study
Authors: Mary T. Bassett, Jarvis T. Chen, Nancy Krieger
Journal: PLoS Medicine (2021)

There are several transcription errors in the text.The third sentence of the subsection of the Abstract titled "Methods and Findings" should read: "As of July 22, 2020, the number of COVID-19 deaths equaled 68,377 for NHW, 29,476 for NHB, 23,256 for Hispanic, 1,143 for NHAIAN, and 6,468 for NHAPI populations; the corresponding population sizes were 186.4 million, 40.6 million, 57.7 million, 2.6 million, and 19.5 million."The sixth sentence of the subsection of the Abstract titled "Methods and Findings" should read: "Similarly, rate ratios for the Hispanic versus NHW population were 7.0 (95%CI 5.8, 8.4; p<0.001), 8.8 (95% CI 7.8, 9.9; p < 0.001), and 7.0 (95% CI 6.6, 7.5; p < 0.001) for the corresponding age strata above, with remaining rate ratios ranging from 1.4 to 5.0."The eighth sentence in the same section should read: "Among NHAPI persons, rate ratios ranged from 2.0 to 2.8 for persons 25-74 years and were 1.4 and 1.1 for persons aged 75-84 and 85+ years, respectively."The final sentence of the first paragraph of the Results should read: "Corresponding proportions for other groups are as follows: 37% and 61% for Hispanic, 45% and 69% for NHAIAN, and 23% and 46% for NHAPI."The third sentence of the third paragraph within the subsection of the Results titled "Rate differences" should read: "Accounting for age distribution and population size differences between racial/ethnic groups, the age-standardized YPLL rate ratio, compared to the NHW population, equaled 6.9 (95% CI 6.9, 6.9; p <0.001) for NHB, 6.4 (95% CI 6.4, 6.4; p < 0.001) for Hispanic, 8.7 (95% CI 8.6, 8.9; p < 0.001) for NHAIAN, and 2.5 (95% CI 2.4, 2.5; p < 0.001) for NHAPI."There are several transcriptions errors in the Table 2.
TCT CONNECT-293 Real-World Experience of Suture-Based Closure Devices: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database
Authors: Brian Case, Sant Kumar, Charan Yerasi, Brian Forrestal, Anees Musallam, Chava Chezar-Azerrad, Nauman Khalid, Evan Shlofmitz Dupe, Lowell Satler, Itsik Ben-Dor, Hayder Hashim, Toby Rogers, Ron Waksman
Journal: Journal of the American College of Cardiology (2020)
Knockout Tumor Microenvironment HO-1 Enhances the Therapeutic Effect of Histone Deacetylase Inhibitor (RGFP966) on B Cell Lymphoma
Authors: Zhen Zhou, Qin Fang, Dan Ma, Tingting Lu, Xiuying Hu, Yudan Liao, Zhengchang He, Jishi Wang
Journal: Blood (2017)
Evaluating the seasonality of growth in infants using a mobile phone application
Authors: Satoshi Narumi, Tetsu Ohnuma, Kenji Takehara, Naho Morisaki, Kevin Y. Urayama, Tomoyuki Hattori
Journal: npj Digital Medicine (2020)

Abstract It has been observed that growth velocity of toddlers and school children shows seasonal variation, while such seasonality is unknown in infants. The aim of this study was to examine whether growth velocity (length and weight) of infants differs by seasons. We assessed longitudinal measurement data obtained for 9,409 Japanese infants whose parents used the mobile phone application, “Papatto Ikuji”, during the period from January 2014 to October 2017. On average, each infant had 4.8 entries for length and 5.4 entries for weight. The mean daily change in sex- and age-adjusted z- scores between two time points was estimated as the growth velocity during that period: ΔLAZ/day and ΔWAZ/day for length and weight, respectively. We analyzed 20,007 ΔLAZ/day (mean, −0.0022) and 33,236 ΔWAZ/day (mean, 0.0005) measurements, and found that ΔLAZ/day showed seasonal differences with increases during summer. We conducted a multilevel linear regression analysis, in which effects of age, sex, nutrition and season of birth were adjusted, showing significant difference in ΔLAZ/day between winter and summer with a mean ΔLAZ/day difference of 0.0026 (95%CI 0.0015 to 0.0036; P &lt; 0.001). This seasonal difference corresponded to 13% of the average linear growth velocity in 6-month-old infants. A modest effect of nutrition on linear growth was observed with a mean ΔLAZ/day difference of 0.0015 (95%CI 0.0006 to 0.0025; P &lt; 0.001) between predominantly formula-fed infants and breastfed infants. In conclusion, we observed that linear growth, but not weight gain, of Japanese infants showed significant seasonality effects represented by increases in summer and decreases in winter.
Adoption of Strategies to Mitigate Transmission of COVID-19 During a Statewide Primary Election — Delaware, September 2020
Authors: Eva Leidman, Noemi B. Hall, Amy E. Kirby, Amanda G. Garcia-Williams, Jose Aponte, Jonathan S. Yoder, Rick Hong, Anthony Albence, Fátima Coronado, Greta M. Massetti
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Elections occurring during the coronavirus disease 2019 (COVID-19) pandemic have been affected by notable changes in the methods of voting, the number and type of polling locations, and in-person voting procedures (1). To mitigate transmission of COVID-19 at polling locations, jurisdictions have adopted changes to protocols and procedures, informed by CDC's interim guidance, developed in collaboration with the Election Assistance Commission (2). The driving principle for this guidance is that voting practices with lower infection risk will be those which reduce the number of voters who congregate indoors in polling locations by offering a variety of methods for voting and longer voting periods. The guidance for in-person voting includes considerations for election officials, poll workers, and voters to maintain healthy environments and operations. To assess knowledge and adoption of mitigation strategies, CDC collaborated with the Delaware Department of Health and Social Services and the Delaware State Election Commission on a survey of poll workers who served during the statewide primary election on September 15, 2020. Among 522 eligible poll workers, 93% correctly answered all three survey questions about COVID-19 transmission. Respondents noted that most voters and poll workers wore masks. However, masks were not always worn correctly (i.e., covering both the nose and mouth). Responses suggest that mitigation measures recommended for both poll workers and voters were widely adopted and feasible, but also highlighted gaps in infection prevention control efforts. Strengthening of measures intended to minimize the risk of poll workers acquiring COVID-19 from ill voters, such as additional training and necessary personal protective equipment (PPE), as well as support for alternative voting options for ill voters, are needed. Adherence to mitigation measures is important not only to protect voters but also to protect poll workers, many of whom are older adults, and thus at higher risk for severe COVID-19-associated illness. Enhanced attention to reducing congregation in polling locations, correct mask use, and providing safe voting options for ill voters are critical considerations to minimize risk to voters and poll workers. Evidence from the Delaware election supports the feasibility and acceptability of implementing current CDC guidance for election officials, poll workers, and voters for mitigating COVID-19 transmission at polling locations (2).
TCT CONNECT-134 Relative Quality of Life Improvement After Transcatheter Aortic Valve Replacement (TAVR) in Patients With Reduced Ejection Fraction.
Authors: Hamza Lodhi, Ramez Morcos, Adithya Mathews, Priya Bansal, Anand Desai, Lu Tianshi, Houman Khalili, Brijeshwar Maini
Journal: Journal of the American College of Cardiology (2020)
THU0108 Antibodies to parvovirus b19 in rheumatoid arthritis and osteoarthritis
Authors: P Athanassiou, K Themeli-Digalaki, A Elezoglou, E Orkopoulou, A Theodorou, R Karidis, C Koutsia-Karouzou, G Vezyroglou
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Parvovirus B19 may cause an acute or chronic polyarthropathy, which in many cases fulfils the criteria of the American College of Rheumatology for the diagnosis of rheumatoid arthritis (RA). Additionally, parvovirus B19 has been implicated in the pathogenesis of RA. <h3>Objectives</h3> The aim was to investigate the presence of antibodies to parvovirus B19 in patients with RA and osteoarthritis (OA). <h3>Methods</h3> In the study were included 50 patients with RA, 24 patients with OA and 26 healthy controls. In all patients IgG and IgM antibodies to parvovirus B19 were measured by indirect immunofluorescence. In patients found to be positive for IgM antibodies to parvovirus B19 results were further confirmed by Western blot. <h3>Results</h3> In 28 of 50 patients with RA (56%) and in 7/26 of the controls (26.9%) IgG antibodies to parvovirus B19 were detected (x2, p &lt; 0.05). In 9 of 24 patients with OA and in 7/26 of controls IgG antibodies to parvovirus B19 were detected (x2, p &gt; 0.05). In 11 of 50 patients with RA (22%) IgM antibodies to parvovirus B19 were detected and the results were further confirmed by Western blot, while in none of the patients with OA and in none of the controls were IgM antibodies observed (x2, p &lt; 0.001 and p &gt; 0.05, respectively). <h3>Conclusion</h3> The prevalence of antibodies to parvovirus B19 was found to be increased in patients with RA as compared to controls. In patients with OA the prevalence of antibodies to parvovirus B19 was found to be comparable to that in controls. These results indicate either that infection with parvovirus B19 may be implicated in the pathogenesis of RA, as previously discussed in the literature, or that some cases of chronic polyarthropathy due to parvovirus B19 may have been misdiagnosed as rheumatoid arthritis.
TCT CONNECT-41 Impact of Chronic Kidney Disease on Coronary Revascularization and In-Hospital Outcomes in Patients With Acute ST-Segment Elevation Myocardial Infarction
Authors: Hemang Panchal, Shimin Zheng, Christopher White, Edward Leinaar, Debabrata Mukherjee, Mamas Mamas, Deepak Bhatt, Hani Jneid, Habib Samady, Roxana Mehran, Shahyar Gharacholou, Timir Paul
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-89 Impact of Pre-Existent Atrial Fibrillation on Clinical Outcomes After Transcatheter or Surgical Aortic Valve Replacement for Severe Aortic Stenosis: An Analysis From the PARTNER 3 Trial
Authors: Ioanna Kosmidou, S. Chris Malaisrie, Isaac George, Vinod Thourani, Angelo Biviano, Mark Russo, David L. Brown, Vasilis Babaliaros, Robert Guyton, Susheel Kodali, James McCabe, Mathew Williams, Philippe Genereux, Michael Lu, Xiao Yu, Bahira Shahim, Maria Alu, John Webb, Michael Mack, Martin Leon
Journal: Journal of the American College of Cardiology (2020)
IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis
Authors: Kristi Basho, Katharina Zoldan, Michael Schultheiss, Dominik Bettinger, Anna-Maria Globig, Bertram Bengsch, Christoph Neumann-Haefelin, Adam Klocperk, Klaus Warnatz, Maike Hofmann, Robert Thimme, Tobias Boettler
Journal: Journal of Hepatology (2020)
TCT CONNECT-235 Coronary Collateral Function Post Successful CTO PCI Using Contemporary Method
Authors: Osama Alsanjari, Grigoris Karamasis, Danielle Keulards, Paul Kelly, Kare Tang, Klio Konstantinou, James Cockburn, David Hildick-Smith, Koen Teeuwen, Thomas Keeble, John Davies
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-195 Percutaneous Patent Foramen Ovale Closure for Migraine With the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data From the Randomized Trials
Authors: Preetham Kumar, Mohammad Mojadidi, Ahmed Mahmoud, Islam Elgendy, Hilary Shapiro, Brian West, Heinrich Mattle, Sherman Sorensen, Bernhard Meier, Stephen Silberstein, Jonathan Tobis
Journal: Journal of the American College of Cardiology (2020)
Exogenous and autocrine growth factors significantly reduce the anti-proliferative and pro-apoptotic effects of curcumin on normal and cancerous epithelial cells
Authors: Chrissy S. Pichot, William Rengifo-Cam, Amar Singh, Azar Owlia, Pomila Singh
Journal: Cancer Research (2005)

812  INTRODUCTION: Curcumin, a natural dietary substance, has been established as a chemoprotective agent that inhibits colon carcinogenesis. In contrast, growth factors such as IGF-II and progastrin (PG) have been shown to exert proliferative and anti-apoptotic effects on both normal and cancerous intestinal epithelial cells. The effects of these growth factors on the inhibitory potency of curcumin have not been examined. Since IGF-II and PG are expressed by the majority of colon carcinomas, we examined the inhibitory efficacy of curcumin on colon cancer cells in the presence of these two relevant growth factors. METHODS: Colon carcinoma (Caco-2) cells express high levels of autocrine IGF-II during their logarithmic growth phase (days 2-5 in culture). Expression of IGF-II rapidly declines as the cells begin to differentiate (days 6-11 in culture). Based on this pattern of expression, Caco-2 cells were treated with curcumin (25-100uM) after 3, 5, 7, or 9 days in culture to determine if the inhibitory efficacy of curcumin correlates with the relative expression of autocrine IGF-II. Rates of proliferation and apoptosis were quantified by cell cycle analysis. Non-transformed intestinal epithelial (IEC-18) cells do not produce autocrine growth factors, but do proliferate in response to exogenous IGF-II or PG. IEC-18 cells were treated with an optimal dose of curcumin (25uM) in the presence or absence of either PG (0.1nM) or IGF-II (10nM). Relative rates of apoptosis were measured by western blot analysis of activated caspase 9, while proliferation was determined by a count of the total number of viable cells. RESULTS: Surprisingly, curcumin was ineffective at inducing apoptosis in Caco-2 cells treated on days 3 and 5 but exerted increasing apoptotic effects in Caco-2 cells on days 7 and 9. The increase in apoptosis suggested a correlation with the naturally declining expression of IGF-II in Caco-2 cells after day 6. In IEC-18 cells, curcumin treatment decreased proliferation and increased apoptosis within 24 hours. However, in the presence of either exogenous PG or IGF-II, the protective effects of curcumin were significantly inhibited. IGF-II was approximately 3 times more effective at interfering with curcumin than was PG. CONCLUSIONS: These unexpected results demonstrate that the protective effects of curcumin can be greatly diminished by the presence of growth factors. Moreover, IGF-II is more effective than PG at overcoming the anti-proliferative and pro-apoptotic effects of curcumin. Thus, the efficacy of curcumin in a patient’s diet may be dictated by the growth factor profile of the carcinoma.
TCT CONNECT-404 Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses: Results From the Disrupt CAD III Optical Coherence Tomography Sub-study
Authors: Richard Shlofmitz, Robert Riley, Ron Waksman, Keith Oldroyd, Gregg Stone, Jonathan Hill, Akiko Maehara, Dean Kereiakes
Journal: Journal of the American College of Cardiology (2020)